Thanks to recent progress in molecular characterization, the identification of the NAB2-STAT6 fusion oncogene has emerged as a specific cytogenetic hallmark for SFT, involved in the overexpression of vascular endothelial growth factor (VEGF). The gene discussed is STAT6; the disease is solitary fibrous tumor.